Regeneron expands in gene editing with Mammoth deal
Bio Pharma Dive
APRIL 25, 2024
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
Verve partners with Lilly on gene editing therapy for heart disease
Bio Pharma Dive
JUNE 15, 2023
Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).
Gene Editing 
322
322 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lilly dives into gene editing
Bio Pharma Dive
NOVEMBER 20, 2020
Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy.
Gene Editing 261
261 
CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder
Bio Pharma Dive
JUNE 15, 2021
A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.
Gene Editing 287
287 
Regeneron, Intellia target neurological diseases in expanded gene editing deal
Bio Pharma Dive
OCTOBER 3, 2023
The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.
Gene Editing 261
261 
The Significance of the MHRA Approval and Upcoming FDA Review of the First Gene Editing Treatment
Worldwide Clinical Trials
NOVEMBER 27, 2023
Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.
Gene Editing 189
189 
Gene editing: beyond the hype
pharmaphorum
JANUARY 29, 2021
Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers. That would just slow the whole field down.
Gene Editing 145
145 
Asklepios partners with ReCode on gene-editing platform
Pharmaceutical Technology
JANUARY 10, 2023
Asklepios BioPharmaceutical has entered a research partnership and option agreement with ReCode Therapeutics for exploring its single-vector gene-editing platform. The new solution will enable complete gene insertion by delivering the gene-editing tool and DNA as mixed cargo to desired targets in one LNP.
Gene Editing 130
130 
Moderna partners with Life Edit for mRNA gene editing therapies
Pharmaceutical Technology
FEBRUARY 23, 2023
Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. The post Moderna partners with Life Edit for mRNA gene editing therapies appeared first on Pharmaceutical Technology.
Gene Editing 147
147 
Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 17, 2024
We are witnessing a revolution in healthcare, driven by advances in genetics, Omics, RNA and CRISPR gene-editing technology, to deliver precision and personalised medicine, said Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics. In […]
Genetic Disease 149
149 
Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup
Bio Pharma Dive
FEBRUARY 28, 2024
The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes that can be used to make genetic medicines.
Gene Editing 176
176 
STAT+: Moderna expands CRISPR gene editing research with ElevateBio partnership
STAT News
FEBRUARY 22, 2023
Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions.
Gene Editing 126
126 
Epigenetic Editing Explodes on the Heels of Gene Editing Success
BioSpace
MARCH 24, 2024
Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.
Gene Editing 140
140 
Verve Therapeutics and Lilly partner to advance gene editing programme
Pharmaceutical Technology
JUNE 15, 2023
Verve Therapeutics and Eli Lilly and Company have entered an exclusive research partnership to advance the former’s preclinical stage in vivo gene editing programme targeting lipoprotein(a) (Lp(a)) to treat atherosclerotic cardiovascular disease (ASCVD). The company will receive a combined upfront payment and equity investment of $60m.
Gene Editing 130
130 
New CRISPR-Based Tool Called PASTE Gene Editing Inserts Large DNA Sequences at Desired Sites
XTalks
DECEMBER 14, 2022
Expanding upon the CRISPR-Cas9 gene editing system, researchers at MIT have designed a new technique called PASTE gene editing that can cut out defective genes and replace them with new genes in a safer and more efficient way. The PASTE gene editing technique was recently published in Nature Biotechnology.
Gene Editing 98
98 
Gene Therapy and Pharmacokinetics
Camargo
JULY 27, 2021
It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. Additionally, gene editing allows us either to remove or to modify harmful genes.
Gene Therapy 238
238 
Gene-editing firm Prime Medicine files $140m public offer
pharmaphorum
FEBRUARY 15, 2024
Gene-editing biotech Prime Medicine has priced its IPO, hoping to raise $140m to advance its pipeline of one-shot therapies for severe genetic disorders.
Gene Editing 65
65 
Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies
Pharmaceutical Technology
MARCH 28, 2023
Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. The gene-editing technology allows for precise, directed changes to genomic DNA.
Gene Editing 235
235 
ElevateBio raises funds to advance cell and gene therapies
Pharmaceutical Technology
MAY 25, 2023
ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.
Gene Therapy 243
243 
Eledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant
BioSpace
MARCH 21, 2024
Tegoprubart, Eledon Pharmaceuticals’ experimental anti-CD40L antibody, was part of the immunosuppressive treatment regimen used following the first-ever transplant of a kidney from a genetically modified pig to a human.
Gene Editing 99
99 
STAT+: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools
STAT News
MARCH 1, 2023
Tessera Therapeutics chief scientist Michael Holmes had just finished presenting a much-anticipated peek at a technology the company had previously said could “ revolutionize genetic medicine ” and “cure nearly any genetic disease.”
Gene Editing 119
119 
New gene-editing technique reverses vision loss in mice
Medical Xpress
MARCH 17, 2023
The study, to be published March 17 in the Journal of Experimental Medicine, uses a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing genetic mutations.
Gene Editing 98
98 
Gene editing DNA deletion sizes reduced with new fusion method developed at WFIRM
Scienmag
MAY 2, 2022
WINSTON-SALEM, NC – May 2, 2022 — Wake Forest Institute for Regenerative Medicine (WFIRM) scientists working on CRISPR/Cas9-mediated gene editing technology have developed a method to increase efficiency of editing while minimizing DNA deletion sizes, a key step toward developing gene editing therapies to treat genetic diseases.
Gene Editing 58
58 
Prime Medicine joins the biotech IPO queue, seeking $140m
pharmaphorum
FEBRUARY 15, 2024
Gene-editing biotech Prime Medicine has priced an initial public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25
Gene Editing 105
105 
Vertex, CRISPR prep filing for gene-editing blood disorder therapy
pharmaphorum
SEPTEMBER 28, 2022
Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this year. The time places exa-cel in pole position to become the first drug developed based on CRISPR/Cas9 gene-editing technology to reach the market.
Gene Editing 59
59 
FDA grants Rare Pediatric Disease status for iECURE’s OTC deficiency therapy
Pharmaceutical Technology
AUGUST 24, 2022
A lead product candidate of the company, GTP-506 is a single-dose gene editing therapy. The ARCUS nuclease vector (GTP-506A) targets gene editing in the PCSK9 gene locus that is well characterised, while the therapeutic donor vector (GTP-506D) introduces the OTC gene to provide the required genetic correction.
Gene Editing 130
130 
AstraZeneca pays record 660% premium for gene editing company LogicBio
pharmaphorum
OCTOBER 4, 2022
AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The post AstraZeneca pays record 660% premium for gene editing company LogicBio appeared first on.
Gene Editing 65
65 
STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
STAT News
SEPTEMBER 16, 2022
Intellia Therapeutics said Friday the first six patients to receive its CRISPR-based treatment for a genetic swelling disorder have safely had small, corrective changes made to dysfunctional DNA inside their liver cells.
DNA 142
142 
STAT+: Mice with two fathers and base-edited baby monkeys highlight potential — and limitations — of hereditable gene editing
STAT News
MARCH 9, 2023
LONDON — Scientists at this year’s genome editing summit spent Tuesday showing the world just how far CRISPR -based medicines for treating human diseases have come in a decade.
Gene Editing 98
98 
Moderna seals pact with Life Edit Therapeutics to tackle genetic diseases with mRNA-based gene editing
BioPharma Reporter
FEBRUARY 23, 2023
The messenger RNA (mRNA) specialist Moderna has teamed up with ElevateBio-owned Life Edit Therapeutics to develop gene editing therapies that are delivered into patients in vivo.
Gene Editing 52
52 
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
pharmaphorum
AUGUST 24, 2021
Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that could be worth up to $1.2 If approved, it could mount a challenge to bluebird bio’s gene therapy Zynteglo, which is already approved in Europe.
Gene Editing 52
52 
Merit-based NSF grant extension supports expansion of gene-editing technology
Scienmag
AUGUST 18, 2020
Credit: Rasgon Lab, Penn State Researchers who developed an improved method of gene editing for the study of arthropods will expand the technology for use in vertebrate species such as mice, fish and birds after receiving new funding from the National Science Foundation.
Gene Editing 61
61 
STAT+: Ahead of genome summit in London, questions linger about CRISPR baby scandal
STAT News
MARCH 3, 2023
Continue to STAT+ to read the full story…
Genome 111
111 
The view of the gene editing pioneer: Shedding light on CRISPR’s role in the COVID-19 pandemic and tackling chemotherapy resistance
BioPharma Reporter
OCTOBER 22, 2020
The use of CRISPR, the genetic scissors that allow scientists to edit the instruction manual of life, DNA, has drawn massive global attention over the last several years.
Gene Editing 90
90 
Commercialization of novel gene-editing technology in beta-thalassemia
pharmaphorum
OCTOBER 13, 2022
Gene therapies and research into them have grown immensely in recent years, offering more novel tools in regenerative medicine to fight disease, including rare diseases and genetic disorders. Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Novartis also recently inked an up-to $1.5
Gene Editing 52
52 
After three years in prison, ‘CRISPR babies’ scientist is attempting a comeback
STAT News
NOVEMBER 29, 2022
He Jiankui, the Chinese biophysicist who created the first gene-edited children , had been quiet since completing a three-year prison sentence in April, leaving many to wonder whether he had plans to return to scientific research. Earlier this month, we got his answer.
Gene Editing 144
144 
Biogen teams up with gene-editing startup Scribe on ALS programme
pharmaphorum
OCTOBER 8, 2020
Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. The post Biogen teams up with gene-editing startup Scribe on ALS programme appeared first on. Jennifer Doudna.
Gene Editing 58
58 
Paper: Congress must clarify limits of gene-editing technologies
Scienmag
OCTOBER 21, 2020
–Genome editing of human embryos represents one of the most contentious potential scientific applications today. But what if geneticists could sidestep the controversy by editing sperm and eggs instead? Credit: Photo by L. Brian Stauffer CHAMPAIGN, Ill.
Gene Editing 88
88 
Gene-editing produces tenfold increase in superbug slaying antibiotics
Scienmag
JANUARY 12, 2021
Martins Scientists have used gene-editing advances to achieve a tenfold increase in the production of super-bug targeting formicamycin antibiotics. Credit: Dr Dino J. The John Innes Centre researchers used the technology to create a new strain of Streptomyces formicae bacteria which over-produces the medically promising molecules.
Gene Editing 53
53 
Biotech Uncloaks Primed for 'Search and Replace' Gene Editing with $315 Million
BioSpace
JULY 12, 2021
The company's technology aims to precisely search out genetic mutations at their precise genome location, limiting concerns about toxicities or unwanted cellular changes.
Gene Editing 72
72 
STAT+: New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors
STAT News
SEPTEMBER 20, 2022
A new CRISPR startup — backed by some big names in venture capital — is planning to develop gene-editing treatments that can insert a genetic sequence of any length, at any location in the DNA strand, according to industry insiders and documents.
DNA 98
98 
How epilepsy researchers are moving the needle past anti-seizure treatments
Pharmaceutical Technology
FEBRUARY 13, 2023
Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. Meanwhile, others are researching the link between gene variation and different responses to treatments.
Research 264
264 
STAT+: At genome-editing summit, experts worry that rule changes on embryo research in China fall short
STAT News
MARCH 6, 2023
LONDON — The first gene-edited children were born in China five years ago , but it’s unlikely to happen again there anytime soon. That was the message Chinese scientists delivered Monday on the opening day of the Third International Summit on Human Genome Editing in London.
Genome 98
98 
Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis
pharmaphorum
JUNE 23, 2022
Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). It is also working with Eli Lilly on in vivo gene-editing drugs against three targets, including one in Duchenne muscular dystrophy, under the terms of a $1.4
Gene Editing 96
96 
Let's personalize your content